Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 74

1.

Parkinson's disease biomarkers: perspective from the NINDS Parkinson's Disease Biomarkers Program.

Gwinn K, David KK, Swanson-Fischer C, Albin R, Hillaire-Clarke CS, Sieber BA, Lungu C, Bowman FD, Alcalay RN, Babcock D, Dawson TM, Dewey RB Jr, Foroud T, German D, Huang X, Petyuk V, Potashkin JA, Saunders-Pullman R, Sutherland M, Walt DR, West AB, Zhang J, Chen-Plotkin A, Scherzer CR, Vaillancourt DE, Rosenthal LS.

Biomark Med. 2017 May;11(6):451-473. doi: 10.2217/bmm-2016-0370. Epub 2017 Jun 23.

PMID:
28644039
2.

Plasma α-synuclein predicts cognitive decline in Parkinson's disease.

Lin CH, Yang SY, Horng HE, Yang CC, Chieh JJ, Chen HH, Liu BH, Chiu MJ.

J Neurol Neurosurg Psychiatry. 2017 Oct;88(10):818-824. doi: 10.1136/jnnp-2016-314857. Epub 2017 May 26.

3.

Multiple modality biomarker prediction of cognitive impairment in prospectively followed de novo Parkinson disease.

Caspell-Garcia C, Simuni T, Tosun-Turgut D, Wu IW, Zhang Y, Nalls M, Singleton A, Shaw LA, Kang JH, Trojanowski JQ, Siderowf A, Coffey C, Lasch S, Aarsland D, Burn D, Chahine LM, Espay AJ, Foster ED, Hawkins KA, Litvan I, Richard I, Weintraub D; Parkinson’s Progression Markers Initiative (PPMI).

PLoS One. 2017 May 17;12(5):e0175674. doi: 10.1371/journal.pone.0175674. eCollection 2017.

4.

Neuropsychological Subgroups in Non-Demented Parkinson's Disease: A Latent Class Analysis.

Brennan L, Devlin KM, Xie SX, Mechanic-Hamilton D, Tran B, Hurtig HH, Chen-Plotkin A, Chahine LM, Morley JF, Duda JE, Roalf DR, Dahodwala N, Rick J, Trojanowski JQ, Moberg PJ, Weintraub D.

J Parkinsons Dis. 2017;7(2):385-395. doi: 10.3233/JPD-171081.

PMID:
28387684
5.

Decrease in Aβ42 predicts dopa-resistant gait progression in early Parkinson disease.

Rochester L, Galna B, Lord S, Yarnall AJ, Morris R, Duncan G, Khoo TK, Mollenhauer B, Burn DJ.

Neurology. 2017 Apr 18;88(16):1501-1511. doi: 10.1212/WNL.0000000000003840. Epub 2017 Mar 22. Erratum in: Neurology. 2017 Jul 4;89(1):107.

6.

Cognitive decline in Parkinson disease.

Aarsland D, Creese B, Politis M, Chaudhuri KR, Ffytche DH, Weintraub D, Ballard C.

Nat Rev Neurol. 2017 Apr;13(4):217-231. doi: 10.1038/nrneurol.2017.27. Epub 2017 Mar 3. Review.

PMID:
28257128
7.

Apolipoprotein E and Alzheimer's disease: the influence of apolipoprotein E on amyloid-β and other amyloidogenic proteins.

Huynh TV, Davis AA, Ulrich JD, Holtzman DM.

J Lipid Res. 2017 May;58(5):824-836. doi: 10.1194/jlr.R075481. Epub 2017 Feb 27. Review.

PMID:
28246336
8.

Narrative Organization Deficit in Lewy Body Disorders Is Related to Alzheimer Pathology.

Grossman M, Irwin DJ, Jester C, Halpin A, Ash S, Rascovsky K, Weintraub D, McMillan CT.

Front Neurosci. 2017 Feb 8;11:53. doi: 10.3389/fnins.2017.00053. eCollection 2017.

9.

Decision-Making Deficits Associated with Amyloidosis in Lewy Body Disorders.

Spotorno N, McMillan CT, Irwin DJ, Clark R, Lee EB, Trojanowski JQ, Weintraub D, Grossman M.

Front Hum Neurosci. 2017 Jan 11;10:693. doi: 10.3389/fnhum.2016.00693. eCollection 2016.

10.

Clinical variables and biomarkers in prediction of cognitive impairment in patients with newly diagnosed Parkinson's disease: a cohort study.

Schrag A, Siddiqui UF, Anastasiou Z, Weintraub D, Schott JM.

Lancet Neurol. 2017 Jan;16(1):66-75. doi: 10.1016/S1474-4422(16)30328-3. Epub 2016 Nov 18.

PMID:
27866858
11.

Harnessing Cerebrospinal Fluid Biomarkers in Clinical Trials for Treating Alzheimer's and Parkinson's Diseases: Potential and Challenges.

Kim D, Kim YS, Shin DW, Park CS, Kang JH.

J Clin Neurol. 2016 Oct;12(4):381-392. doi: 10.3988/jcn.2016.12.4.381. Review.

12.

CSF Biomarkers and Its Associations with 18F-AV133 Cerebral VMAT2 Binding in Parkinson's Disease-A Preliminary Report.

Gao R, Zhang G, Chen X, Yang A, Smith G, Wong DF, Zhou Y.

PLoS One. 2016 Oct 20;11(10):e0164762. doi: 10.1371/journal.pone.0164762. eCollection 2016.

13.

Cerebrospinal Fluid Alzheimer's Disease Biomarkers Across the Spectrum of Lewy Body Diseases: Results from a Large Multicenter Cohort.

van Steenoven I, Aarsland D, Weintraub D, Londos E, Blanc F, van der Flier WM, Teunissen CE, Mollenhauer B, Fladby T, Kramberger MG, Bonanni L, Lemstra AW; European DLB consortium.

J Alzheimers Dis. 2016 Aug 18;54(1):287-95. doi: 10.3233/JAD-160322.

14.
15.

Presence of cerebral amyloid modulates phenotype and pattern of neurodegeneration in early Parkinson's disease.

McMillan CT, Wolk DA.

J Neurol Neurosurg Psychiatry. 2016 Oct;87(10):1112-22. doi: 10.1136/jnnp-2015-312690. Epub 2016 Jun 9.

16.
17.

Plasma EGF and cognitive decline in Parkinson's disease and Alzheimer's disease.

Lim NS, Swanson CR, Cherng HR, Unger TL, Xie SX, Weintraub D, Marek K, Stern MB, Siderowf A; PARS Investigators; Alzheimer's Disease Neuroimaging Initiative, Trojanowski JQ, Chen-Plotkin AS.

Ann Clin Transl Neurol. 2016 Mar 29;3(5):346-55. doi: 10.1002/acn3.299. eCollection 2016 May.

18.

The Mental Status Examination in Patients With Suspected Dementia.

Grossman M, Irwin DJ.

Continuum (Minneap Minn). 2016 Apr;22(2 Dementia):385-403. doi: 10.1212/CON.0000000000000298. Review.

19.

CSF biomarkers associated with disease heterogeneity in early Parkinson's disease: the Parkinson's Progression Markers Initiative study.

Kang JH, Mollenhauer B, Coffey CS, Toledo JB, Weintraub D, Galasko DR, Irwin DJ, Van Deerlin V, Chen-Plotkin AS, Caspell-Garcia C, Waligórska T, Taylor P, Shah N, Pan S, Zero P, Frasier M, Marek K, Kieburtz K, Jennings D, Tanner CM, Simuni T, Singleton A, Toga AW, Chowdhury S, Trojanowski JQ, Shaw LM; Parkinson’s Progression Marker Initiative.

Acta Neuropathol. 2016 Jun;131(6):935-49. doi: 10.1007/s00401-016-1552-2. Epub 2016 Mar 28.

20.

Olfactory impairment predicts cognitive decline in early Parkinson's disease.

Fullard ME, Tran B, Xie SX, Toledo JB, Scordia C, Linder C, Purri R, Weintraub D, Duda JE, Chahine LM, Morley JF.

Parkinsonism Relat Disord. 2016 Apr;25:45-51. doi: 10.1016/j.parkreldis.2016.02.013. Epub 2016 Feb 19.

Supplemental Content

Support Center